What an AI agent reads on Oncotab
An assistant's crawler fetches the page once, without running JavaScript, and reads the text, the structured data and the links. Below is what it gets from oncotab.com, taken from the copy the scanner kept.
4,808
characters of text without JavaScript
Organization
structured data for the business
0
of 3 AI crawlers turned away at the edge
The words an agent gets
Title: OncoTAb | Targeting Pancreatic Cancer Through tMUC1 · language en-US. First 1,800 of 4,808 characters:
OncoTAb | Targeting Pancreatic Cancer Through tMUC1 Skip to content ORDER NOWSEEKING PARTNERS Open mobile menuClose mobile menu HOME ABOUT SCIENCE PRODUCTS & PIPELINE NEWS CONTACT tMUC1-Targeted Therapeutics Targeting Pancreatic Cancer Differently OncoTAb is developing tumor-targeted therapies designed to find and attack pancreatic cancer through a tumor-specific form of MUC1. Our proprietary tMUC1-targeting platform is being advanced through two therapeutic approaches: targeted radiotherapy and T-cell engagement. Explore Our Pipeline → Our Science Longitudinal SPECT/CT imaging demonstrates progressive tumor accumulation and sustained retention of 111In-labeled hTAB004, a full-length humanized antibody targeting tMUC1. Pancreatic Cancer Needs New Approaches Pancreatic cancer remains one of the most difficult cancers to treat. The disease is frequently diagnosed after it has advanced, and its aggressive biology and dense tumor microenvironment create substantial barriers to effective therapy. At OncoTAb, we are developing therapies around a different premise: find a target that distinguishes cancer from normal tissue—and use it to attack the tumor selectively. Our target is tMUC1. One Cancer-Associated Target. Multiple Ways to Attack the Tumor. tMUC1: A Distinctive Tumor-Associated Form of MUC1 MUC1 is normally present on epithelial cells. During malignant transformation, changes in its expression and glycosylation expose unique regions of the molecule, creating the tumor-associated form known as tMUC1. OncoTAb's proprietary targeting technology was developed to recognize tMUC1 while minimizing binding to the normal form of MUC1. Importantly, the targeting agent exhibits minimal binding to circulating tMUC1 while strongly recognizing tMUC1 presented on the tum
What it can say about the business
| A business type in JSON-LD | Organization |
| Name | OncoTAb |
| Telephone | no |
| Address | no |
| Opening hours | no |
| Menu or price list | nothing |
| Cuisine in structured data | no |
| JSON-LD blocks | 1 (BreadcrumbList, EntryPoint, ImageObject, ListItem, Organization, PropertyValueSpecification) |
The links it would act on
| Link | Role | Where it goes |
|---|---|---|
| oncotab.com/order-now/ | ordering | the business's own site |
Everything here comes from fetching the homepage once as a crawler. The report turns it into a score and a list of fixes, with code to paste.